Reimagining nuclear materials for the future of medicine

May 21, 2026, 1:46PMNuclear NewsTim Tinsley and Katie Baverstock-Hunt

Nuclear medicine has come a long way since Henri Becquerel first observed the penetrating energy of radioactive materials in 1896. Today, technetium-99m alone is used in more than 40 million diagnostic procedures every year—from cardiovascular imaging and bone scans to cancer detection—making it the undisputed workhorse of nuclear medicine. That single statistic tells you something important: An enormous portion of modern diagnostic medicine rests on a surprisingly narrow foundation, one built around a small number of aging research reactors that were never originally designed for continuous isotope production.

To continue reading, log in or create a free account!

Related Articles

ANSTO-designed target increases Mo-99 yield

February 25, 2026, 1:00PMNuclear News

The Australian Nuclear Science and Technology Organization (ANSTO) announced that it has made progress on a more cost-effective way to produce the medical radioisotope molybdenum-99, with less...

Mirion announces appointments

February 12, 2026, 3:46PMNuclear News

Mirion Technologies has announced three senior leadership appointments designed to support its global nuclear and medical businesses while advancing a company-wide digital and AI strategy. The...